Introduction
CS-023 (RO4908463, formerly R-115685; Fig. 1 ) is a new 2-substituted 1beta-methyl carbapenem antibiotic with a unique guanidine-pyrrolidine side chain which confers exceptionally broad-spectrum activity against diverse hospital pathogens, including methicillinresistant Staphylococcus aureus and Pseudomonas aeruginosa.
1-3)
Together with antimicrobial activities, a long plasma half-life is one of the most important factors determining the clinical e‹cacy of carbapenem antibiotics. Many studies on the pharmacokinetics W pharmacodynamics of beta-lactam antibiotics, including carbapenem antibiotics, have revealed that the e‹cacy depends on the period of duration when the serum concentration exceeds the minimum inhibitory concentration against target pathogens. [4] [5] [6] In clinical pharmacokinetic studies in healthy volunteers, CS-023 showed a plasma half-life of nearly 2 hr 7) which is two times longer than those of other carbapenem antibiotics such as meropenem 8) (Table 1) . Renal excretion as a parent drug is the main elimination pathway of carbapenem antibiotics in humans, including CS-023. The renal clearance of unbound CS-023 is almost comparable with a glomerularˆltra-tion rate (GFR) of 125 mL W min. 9) On the other hand, the renal clearance value of unbound meropenem is greater than that of GFR ( Table 1 ) and is reduced to values approximating GFR by the co-administration of probenecid, a typical inhibitor of the renal organic anion transport system. 8) This information strongly suggests the involvement of tubular secretion in the renal excretion of meropenem.
We demonstrated previously in a renal clearance study on CS-023 and meropenem using rabbits that meropenem undergoes renal tubular secretion via probenecid-sensitive transporters, but CS-023 does not.
10) The renal clearance of unbound CS-023 was equal to GFR, and was not aŠected by co-administration of probenecid or p-aminohippurate (PAH). On the other hand, the renal clearance of unbound meropenem was three-fold higher than GFR, and was decreased signiˆcantly by the co-administration of probenecid, but not PAH, up to the level of GFR. The co-administration of probenecid also signiˆcantly decreased the renal cortex W plasma concentration ratio of meropenem. These observations suggest the existence of a probenecid-sensitive transport system(s) across the membranes of tubular cells for meropenem but not for CS-023, indicating diŠerent mechanisms for renal excretion of these two carbapenem antibiotics.
Renal tubular secretion is composed of two membrane translocation steps in a series, i.e. the uptake by the renal proximal tubule from blood across the basolateral membrane of the epithelial cells followed by the eOEux from the renal tubule cells into the tubular lumen across the apical membrane. The membrane transport is mediated by transporters located in each membrane of the cells. 11, 12) Organic anion transporters and organic cation transporters are the major transporters involved in the proximal renal tubular secretion of various drugs such as beta-lactam antibiotics and H2-receptor antagonists. [13] [14] [15] In the human proximal renal tubule, it has been reported that the human organic anion transporters (hOAT) 1, hOAT2, hOAT3, and human organic cation transporters (hOCT) 1 and hOCT2 are localized in the basolateral membrane, [16] [17] [18] [19] [20] and that hOAT4 is localized in the apical membrane.
21)
The present study is aimed at characterizing the transport mechanisms of CS-023 and meropenem in the kidney. We conducted in vitro studies on the uptake of [
C]CS-023 and [
14 C]meropenem using hOAT1-, hOAT3-, hOAT4-, hOCT1-, and hOCT2-expressing HEK293 cells.
Materials and Methods
Chemicals: Unlabeled CS-023 and meropenem were synthesized at Sankyo Co., Ltd. (Tokyo, Japan). [ 14 C]-CS-023 and [
14 C]meropenem were synthesized at Daiichi Pure Chemicals Co., Ltd. (Ibaraki, Japan). All other chemicals were commercially available, of reagent grade and were used without any puriˆcation.
Stable expression of hOCT1, hOCT2, hOAT1, hOAT3 and hOAT4 cDNAs in HEK293 cells: The open reading frames of hOCT1, hOCT2, hOAT1, hOAT3 and hOAT4 cDNA were cloned and subcloned into a pcDNA3.1(-) (Invitrogen, CA, USA), and each plasmid were introduced into HEK293 cells (Japan Health Sciences Foundation, Tokyo, Japan) by lipofection using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. The selection of infected cells was performed by culturing them in the presence of 800 mg W mL G418 sulfate. HEK293 cells were grown in Dulbecco's Modiˆed Eagle Medium supplemented with 10z fetal bovine serum, 100 U W mL penicillin, 100 mg W mL streptomycin and 400 mg W mL G418 sulfate at 379 C with 5z CO 2 and 95z humidity. It was conˆrmed that these transporter-expressing cells have speciˆc transport activities for typical substrates such as tetraethylammonium for hOCT1 and 2, and PAH for hOAT1, and estrone sulfate for hOAT3 and 4.
Transport study: Transport studies were carried out as described previously. 22) Each transporter-expressing cells and vector-transfected cells were seeded onto poly-L-lysine and poly-L-ornithine precoated 12 well Multiwell cell culture plates (BD Biosciences) at a density of 5 cells W well, and cultured for three days. These cells were incubated for 24 h before starting the experiments with culture medium supplemented with 5 mM sodium-butyrate (SIGMA-ALDRICH). After the culture medium was removed from the Multiwell tissue culture plates which had been seeded with Each transporter-expressing cells and vector-transfected cells in advance, these cells were preincubated with prewarmed with Krebs-Henseleit buŠer (118 mM NaCl, 23.8 mM NaHCO3, 4.83 mM KCl, 0.96 mM KH2PO4, 1.20 mM MgSO4, 12.5 mM HEPES, 5 mM glucose and 1.53 mM CaCl2 adjusted to pH 7.4) at 379 C for 15 min. Then, uptake was initiated by adding the radiolabeled ligands to the incubating buŠer in the presence and absence of inhibitors. The uptake was terminated at designated times by adding ice-cold Krebs-Henseleit buŠer. The radioactivity in the cell lysate and incubation medium was determined by a liquid scintillation counter. The radioactivity concentration was considered to be the ligand concentration based on the fact that CS-023 and meropenem were stable in the incubation mixture with HEK293 cells for at least 30 min (data not shown). The remaining aliquots of cell lysates were used to determine protein concentrations by the method of Lowry et al. 23) with bovine serum albumin as a standard. The ligand uptake is given as the cell-to-medium concentration ratio determined as the amount of ligand associated with the cells divided by the medium concentration. The speciˆc uptake was obtained by subtracting the uptake by vector-transfected cells from that by the cells expressing each transporter.
Kinetic analyses: The kinetic parameters were obtained using the following equation (Michaelis-Menten equation):
where v is the uptake rate of the substrate (pmol W min W mg protein), S is the substrate concentration in the medium (mM), Km is the Michaelis-Menten constant (mM) and Vmax is the maximum uptake rate (pmol W min W mg protein). The initial uptake velocity data wereˆtted to the equation by a nonlinear regression analysis with weighting as the reciprocal of the observed values, and the Damping Gauss Newton Method algorithm was used forˆtting. The inhibition constants (Ki) for hOAT3-mediated transport of [
14 C]meropenem were calculated assuming competitive inhibition. This assumption is based on the observation that various beta-lactam antibiotics competitively inhibit the organic anion uptake mediated by hOATs.
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Statistical analysis: Data represent the mean±S.E. (n＝3). Statistical diŠerences were determined using a Dunnett's two-tailed t test. DiŠerences were considered signiˆcant at pº0.05.
Results
Uptake of CS-023 and meropenem by transporterexpressing HEK293 cells: Figure 2 shows the uptake of ]meropemen by hOAT1 and hOAT3-expressing cells, but not by hOCT1-, hOCT2-or hOAT4-expressing cells, was signiˆcantly higher than that by the vector-transfected cells. Although the hOAT1-mediated uptake was not statistically signiˆcant, both hOAT1 and hOAT3 were considered to recognize [ 14 C]meropemen as a substrate. Figure 3 shows the time proˆles of the uptake of [ 14 C]meropemen by hOAT3-expressing cells and vectortransfected HEK293 cells, and the linearity of the uptake was maintained until 30 min. The hOAT3-mediated uptake of [ 14 C]meropemen showed saturation kinetics and followed the Michaelis-Menten equation (Fig. 4) . The kinetic parameters for the uptake by hOAT3 were determined by a nonlinear regression analysis and estimated to be 847±160 mM as Km value and 48.5±7.5 pmol W min W mg protein as V max . On the other hand, the kinetic parameters for the hOAT1-mediated transport of meropenem could not be obtained because the amount of uptake was too low for parameter estimation.
EŠects of typical inhibitors on hOAT3-mediated transport of meropenem: The cis-inhibitory eŠects of several inhibitors on the hOAT3-mediated uptake of [ 14 C]meropemen were investigated (Fig. 5) . Probenecid, PAH and benzylpenicillin (BZP) inhibited the uptake of 
Discussion
Pharmacokinetic data in humans and animals have suggested that CS-023 is excreted into the urine predominantly by glomerularˆltration 7) and this renal handling results in its long plasma half-life compared with meropenem, which undergoes renal tubular secretion in addition to glomerularˆltration. 8) In this study, to characterize the renal transport mechanisms of CS-023 and meropenem, we examined the uptake of [ 14 C]CS-023 and [ 14 C]meropenem by human renal transporters, hOAT1, hOAT3, hOAT4, hOCT1 and hOCT2, which are representative transporters responsible for the renal tubular secretion of several drugs. It was demonstrated in the present study that CS-023's lack of recognition by transporters mediating the renal tubular secretion of drugs is very likely to be attributed to the absence of net renal tubular secretion in humans. CS-023 was not transported by hOAT1-, hOAT3-, hOAT4-, hOCT1-, or hOCT2-expressing HEK293 cells (Fig. 2) . Together with our previousˆnding that the renal clearance of unbound CS-023 was comparable with GFR, this observation supports the contention that net renal tubular secretion is not involved in the renal excretion of CS-023 in humans. The renal handling of CS-023 results in a long plasma half-life of around 2 hr in humans, and leads to its e‹cacy in a clinical setting due to its extended time above the minimum inhibitory concentration against target pathogens, which is one of the most important parameters in determining e‹cacy. In addition, CS-023 potentially has less risk of drug-drug interaction via transporter-mediated active secretion in the renal tubule, because the renal clearance of CS-023 is not dependent on the transporters, as shown in this study. This observation is consistent with the previousˆnding that renal excretion of CS-023 in rabbits was not aŠected by co-administration of typical organic anion transporter inhibitors such as probenecid or PAH. 10) As for meropenem, it was indicated in the present study that hOAT1-and hOAT3-mediated renal tubular secretions are involved in the renal excretion mechanism (Fig. 2) . These transporters are reported to be located at the basolateral membrane in the renal tubular cells and are deeply involved in the renal tubular secretion process for such drugs. Thus, a short plasma half-life of meropenem compared with CS-023 would be due to the involvement of transporters-mediated renal tubular secretion. Although in the present study we were not able to examine the transport mechanism from the tubular cells to the lumen across the apical membrane, Uchino et al. have recently reported that Npt1, an inorganic phosphate transporter, participates in the renal secretion of a penem antibiotic. 24) Transporter-mediated renal secretion for meropenem may increase the potential risk of drug-drug interactions. Bax et al. reported that the renal clearance of meropenem decreased from 201 mL W min to 129 mLW min, a value comparable to the GFR, by co-administration of probenecid in humans. 8) In the study, plasma concentrations of probenecid were not measured, however, they were estimated to be more than 150 mg W mL according to the pharmacokinetic data of probenecid reported in the literature. 25) The unbound plasma concentrations are calculated to be more than 16 mM using a reported unbound fraction of probenecid in human plasma, 11z. 25) In the present study, the Ki value of probenecid against the hOAT3-mediated transport of meropenem was 3.76 mM (Fig. 5) . A previous report shows the Ki value of probenecid against hOAT1-mediated transport is about 10 mM.
27) Therefore, it is very likely that the unbound probenecid in the plasma inhibited hOAT1-and hOAT3-mediated tubular secretion of meropenem.
This study gives theˆrst evidence for meropenem being a substrate of renal transporters, hOAT1 and hOAT3, even though the renal tubular secretion of meropenem has been long suggested in clinical pharmacokinetic studies.
8) The hOAT3-mediated uptake of meropenem was saturable (Fig. 4) , and was inhibited by typical hOAT3 inhibitors such as probenecid and benzylpenicillin (Fig. 5) , while the kinetic parameters for the hOAT1-mediated transport could not be obtained due to the relatively low intensity of the meropenem transport. hOAT3 transports estrone sulfate, methotrexate and cimetidine, with Km values of 6.3, 10.9 and 57.4 mM, respectively. 17, 26) Therefore, meropenem (Km: 847 mM) should be categorized as a compound with low transport a‹nity for hOAT3. The typical OAT3 inhibitors, probenecid and BZP, inhibited the uptake of meropenem via hOAT3 with Ki values of 3.76 and 202 mM, respectively (Fig. 5) , which were similar to those in inhibiting the uptake of estrone sulfate, a prototypical substrate for hOAT3, reported in the literature to be 9.0 and 100 mM, respectively. 27, 28) Theseˆndings suggest that estrone sulfate and meropenem bind to the same site on hOAT3 serving as a competitive inhibitors.
One possible explanation for the diŠerent a‹nities of CS-023 and meropenem to hOAT1 and hOAT3 is their diŠerent charge status at physiological pH. Both CS-023 and meropenem are zwitter-ionic compounds (Fig. 1) . CS-023 possesses an anionic moiety, the carboxyl group (pKa 2.44), and two cationic moieties, the pyrrolidine group (pKa 6.86) and the guanidine group (pKa À12), in the molecule (Kondo et al., unpublished observation). On the other hand, meropenem possesses an anionic moiety, the carboxyl group (pKa 2.8), and a cationic moiety, the methyl-pyrrolidine group (pKa 7.4), in the molecule. 29) As shown in Table 1 , CS-023 molecules do not exist as an anion, whereas, 50z of meropenem molecules exist as an anion at physiological pH (7.4) as calculated using the Henderson-Hasselbalch equation. 30) We postulate that CS-023 was not recognized by hOAT1 and W or hOAT3 because none of the molecules exist as an anionic form at physiological pH. Alternatively, the bulkiness and W or hydrophilicity of the molecules may also be important physicochemical characteristics for determining recognition by the transporters. CS-023 has a bulky side chain (higher molecular weight) and greater hydrophilic properties (lower partition coe‹cient) compared with meropenem ( Table 1) . Ullrich et al. 31) studied the recognition of substrates to renal organic anion and cation transport systems by employing the stop-‰ow peritubularcapillary microperfusion method. They reported that numerous zwitter-ionic compounds interact with both renal organic anion and cation transport systems, and have shown the importance of hydrophobicity and partial charge, but not that of the net charges of the substrates. On the other hand, Brendt and Wright 32) have indicated that the degree of ionization plays a critical role in the binding of a substrate to hOCT2 using CHO cells stably expressing hOCT2. Further information is needed to clarify the key factors which determine substrate speciˆcity to the transporters.
In the present study, we have demonstrated that meropenem is a substrate for hOAT1 and hOAT3, but that CS-023 is not recognized as a substrate by any of the transporters tested. Theseˆndings support the observations in humans and animals that transporter mediated tubular secretion is involved in the renal clearance of meropenem, but not of CS-023. The CS-023's lack of the transporters-mediated renal excretion is one of the reasons for the longer plasma half-life of CS-023 in humans.
